

03-25-2003

U.S. Department of Commerce  
Patent and Trademark Office



EET

102399514

3-25-03

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies):</p> <p>Aventis Pharmaceuticals Products Inc.</p> <p><input type="checkbox"/> Individual(s)                      <input type="checkbox"/> Association</p> <p><input type="checkbox"/> General Partnership              <input type="checkbox"/> Limited Partnership</p> <p><input checked="" type="checkbox"/> Corporation- Delaware</p> <p><input type="checkbox"/> Other _____</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and Address of receiving party(ies)</p> <p>Name:      Aventis Pharmaceuticals Inc.</p> <p>Address:    (Mail Stop: BW-D-335) Route #202-206-N, P. O. Box 6800, Bridgewater, NJ 08807-0800</p>
---	---

<p>3. Nature of conveyance:</p> <p><input type="checkbox"/> Assignment                      <input type="checkbox"/> Merger</p> <p><input type="checkbox"/> Security Agreement              <input checked="" type="checkbox"/> Change of Name</p> <p><input type="checkbox"/> Other _____</p> <p>Execution Date: <u>December 31, 2001</u></p>	<p><input type="checkbox"/> Individual(s) citizenship _____</p> <p><input type="checkbox"/> Association _____</p> <p><input type="checkbox"/> General Partnership _____</p> <p><input type="checkbox"/> Limited Partnership _____</p> <p><input checked="" type="checkbox"/> Corporation - Delaware _____</p> <p><input type="checkbox"/> Other _____</p> <p>If assignee is not domiciled in the United States, a domestic representative designation is attached: <input type="checkbox"/> Yes <input type="checkbox"/> No (Designations must be a separate document from assignment) Additional name(s) &amp; address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
--	---

<p>4. Application number(s) or registration number(s):</p>	
<p>A. Trademark Application No.(s)</p> <p>03/26/2003 GTOM11 00000001 774417</p> <p>01 FC:8521                      40.00 OP</p> <p>02 FC:8522                      1200.90 OP</p>	<p>B. Trademark Registration No.(s) 774417</p> <p>(SEE ATTACHED SCHEDULE)</p> <p>Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p>	<p>6. Total number of applications and registrations involved: <u>50</u></p>
<p>Midge M. Hyman, Esq. Cowan, Liebowitz &amp; Latman, P.C. 1133 Avenue of the Americas New York, NY 10036-6799</p>	<p>7. Total fee (37 CFR 3.41)..... \$ <u>1265.00</u></p> <p><input checked="" type="checkbox"/> Enclosed</p> <p><input checked="" type="checkbox"/> Any deficiency is authorized to be charged to Deposit Account No. 03-3415.</p>

<p>Repln. Ref: 03/26/2003 GTOM11 0015160600</p> <p>DA#:033415 Name/Number:774417</p> <p>FC: 9204                      \$50.00 CR</p>	<p>8. Deposit Account No. <u>03-3415</u></p> <p>(Attach duplicate copy of this page if paying by deposit account)</p>
--	---

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

Midge M. Hyman                      [Signature]                      3/24/03

Name of Person Signing                      Signature                      Date

Total number of pages including cover sheet, attachments, and document: 5

Mail to: U.S. Patent and Trademark Office, Office of Public Records, Crystal Gateway 4, Room 335, Washington, DC 20231

MARK	APPLN/REGN NO.	
ANTHRA-DERM	774417	1
BENZACLIN	2502310	2
BENZAGEL	982461	3
BENZAGEL	2162103	4
BENZAGEL	995775	5
BENZAGEL WASH	2553208	6
BENZAGEL WASH	2550460	7
BENZAMYCIN	1226427	8
CARAC	78/034172	9
DERMIK	793936	10
DERMIK SYMBOL	2112303	11
DRITHO-SCALP	1387212	12
DRITHOCREME	1255064	13
E DESIGN	2476183	14
HYTONE	686577	15
KLARON	735930	16
KLARON DESIGN	2202011	17
NORITATE	2213312	18
SHEPARD'S	2231536	19
SULFACET-R	812897	20
VYTONE	736295	21
ZETAR	941282	22
ASCRIPTIN	826772	23
AZMACARE	2036029	24
AZMACORT	1525186	25
CALEL-D	1369780	26
DDAVP	1997079	27
DILACOR	2137371	28
DRI-PAK	2261490	29
DRY NIGHTS FOR GOOD MORNINGS	2391866	30
DRYNIGHTS	75/547254	31
DRYNIGHTS.COM	75/547186	32
FERMALOX	801224	33
GRAM POSITIVE	2461970	34
MAALOX	1949046	35

MARK	APPLN/REGN NO.	
MAALOX	549313	36
NASACORT	1538836	37
NASACORT and design	2008763	38
NASACORT INHALER Design	1935142	39
NICOBID	1088505	40
NITROSPAN	1266827	41
ORASTREP	78/031594	42
ORASTREP	78/021255	43
PACT	2210152	44
PENETREX	1853453	45
PERDIEM	1687540	46
RESPIPAC	2186701	47
TUSSAR	632531	48
WORKING THROUGH MENOPAUSE	2448264	49

**CERTIFICATE OF AMENDMENT TO THE  
CERTIFICATE OF INCORPORATION  
OF  
AVENTIS PHARMACEUTICALS PRODUCTS INC.**

The undersigned, Edward H. Stratemeier, Vice President and Owen K. Ball, Jr., Assistant Secretary of Aventis Pharmaceuticals Products Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), on behalf of the Corporation, hereby certify as follows:

**FIRST:** That the Board of Directors of the Corporation, by the unanimous written consent of its members, as filed with the minutes of the Board of Directors, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation amending the First Article thereof so that, as amended, said Article shall be and read as follows:

"FIRST: The name of the corporation is:

**AVENTIS PHARMACEUTICALS INC."**

**SECOND:** That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.


**THIRD:** That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

**FOURTH:** The effective date of this amendment is December 31, 2001 at 10:30 pm.

**IN WITNESS WHEREOF**, we, Edward H. Stratemeier, Vice President and Owen K. Ball, Jr., Asst. Secretary of Aventis Pharmaceuticals Products Inc., have signed this Certificate under the corporate seal of the Corporation on the 31<sup>st</sup> day of December 2001.

Aventis Pharmaceuticals Products Inc.

  
Edward H. Stratemeier, Vice President


  
Owen K. Ball, Jr. Asst. Secretary

# Delaware

PAGE 1

*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "AVENTIS PHARMACEUTICALS PRODUCTS INC.", CHANGING ITS NAME FROM "AVENTIS PHARMACEUTICALS PRODUCTS INC." TO "AVENTIS PHARMACEUTICALS INC.", FILED IN THIS OFFICE ON THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2001, AT 10:50 O'CLOCK P.M.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

0631221 8100

AUTHENTICATION: 1681332

020188276

DATE: 03-21-02

TRADEMARK

RECORDED: 03/25/2003

REEL: 002691 FRAME: 0869